ReviewJournal of clinical laboratory analysis2026
Recent Advances in Thalassemia Research: A Comprehensive Assessment From Diagnostic Technologies to Clinical Treatment.
Review in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThalassemia is a common hereditary blood disorder characterized by impaired globin synthesis, leading to anemia and a variety of related complications. With the rapid advances in genomics and molecular biology, remarkable progress has been made in this field in recent years, especially in the in-depth exploration of genetic mechanisms, the innovation of diagnostic techniques and the continuous update of therapeutic strategies. It is worth noting that with the emergence of new treatment strategies such as gene therapy and stem cell transplantation, offer new hope for patients. Despite significant progress, further research is needed to address the limitations of existing treatment methods and optimize long-term management for patients.
methodsThis review introduces the epidemiology, pathogenic mechanisms, and related complications of thalassemia.
resultsIt also highlights innovations in the diagnosis of thalassemia (such as TGS and Genomics technologies) and treatment advancements (such as CRISPR/Cas9, HSCT, and Luspatercept) and their limitations, and explores why transformative tools have not been fully utilized in regions with high prevalence of thalassemia.
conclusionsUnlike existing reviews that focus solely on either diagnostic or therapeutic aspects, this article integrates both perspectives with an emphasis on clinical accessibility. It aims to provide sustainable and equitable management guidance for clinicians, researchers, and policymakers involved in thalassemia care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.